Why has Reddy Labs been outperforming in the markets of late?

Dr. Reddy’s Laboratories surged 3.4% to Rs4,554 post launch of its generic version of fesoterodine fumarate to treat overactive bladder in the US markets. This is already approved by USFDA in 4 mg and 8 mg tablets. Its annual US market is estimated at $211 million. Its next big focus area for the Indian market is going to be Nutraceuticals and OTC segments where its presence is currently quite small.